#SobatINAF Jakarta, 20 April 2022 bertempat di kantor PWNU DKI Jakarta telah dilakukan Penandatanganan Perjanjian Kerja Sama Peluncuran AptameX, Alat Test Diagnostik terbaru berbasis teknologi DNA Aptamer antara PWNU DKI Jakarta, Indofarma dan Achiko.

Following last week's announcement, Achiko is pleased to report stronger than expected demand for AptameX and is planning to deliver over 2 million kits in a shorter timeframe than previously contemplated to meet demand, and is commencing first deliveries. bit.ly/3LjkSOd

Achiko will publish its 2021 annual report on 31 August 2022 at the latest. More information can be found here: bit.ly/3zLKm1Y #achiko #aptamex #annualreport

Achiko has successfully completed a production test with PT Indofarma, Tbk PT Indofarma Tbk as a precursor to mass production of the Company's Generation 2 AptameX™ Covid-19 test kit. More here ➡️ bit.ly/3zAkKGn #indonesia #covidtesting #healthtech

Following pilot production with manufacturing partner PT Indofarma Tbk, Achiko is now commencing commercial deliveries of the Company's Generation 2 AptameX™ #Covid19 test kit to Nahdlatul Ulama DKI (NU) and other commercial clients in #Indonesia Read: bit.ly/3USyNz3

Achiko will be holding a corporate update webcast for all shareholders and investors on Tuesday, November 22, 2022 at 3.00pm CET/9.00am EST. Details of the webcast can be found here: bit.ly/3UFcehC #healthtechnology #shareholder #investor #webcast

Achiko issues a convocation notice to its shareholders for its Annual General Meeting on 20 December 2022. bit.ly/3gy9Zht #achiko #agm2022 #annualgeneralmeeting

Achiko held its Annual General Meeting on December 20 and is pleased to announce that all resolutions were duly passed. The Board of Directors would like to thank all those who exercised their rights as shareholders in this way. Details can be found here: bit.ly/3FK5yZx

As Achiko is proceeding to sales and is currently going through external validation, we are proud to report that early results indicate AptameX's strong performance against other forms of #COVID19 testing. See the test performance here: bit.ly/3Vhij3n